If you are interested in attending, please register at the following link: *https://respond.niaid.nih.gov/conferences/AMDW/Pages/default.aspx* by September 10, 2012. There is no registration fee for the workshop. Early registration is recommended because seating is limited. If you need special accommodations due to a disability, please contact Dr. Judy Hewitt (see **FOR FURTHER INFORMATION CONTACT**) at least 7 days in advance of the workshop.

FOR FURTHER INFORMATION CONTACT: Dr. Judy Hewitt, Office of Biodefense Research Affairs, Division of Microbiology and Infectious Diseases, NIAID, at telephone 301–402–4197 or telefax 301–480–1263 or email *AMworkshopSep2012@mail.nih.gov* (Subject line: Animal Model Workshop).

Dated: July 18, 2012.

Lawrence A. Tabak,

Deputy Director, NIH.

[FR Doc. 2012–18168 Filed 7–24–12; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Cancer Biology.

Date: August 14, 2012.

Time: 12:00 p.m. to 3:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Charles Morrow, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6202, MSC 7804, Bethesda, MD 20892, 301–451–4467, *morrowcs@csr.nih.gov.*

Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Healthcare Delivery and Methodologies.

Date: August 28, 2012.

Time: 2 p.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Melinda Jenkins, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3156, MSC 7770, Bethesda, MD 20892, 301–437–7872, *jenkinsml2@mail.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: July 18, 2012.

Carolyn A. Baum,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2012–18055 Filed 7–24–12; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive License: Use of Glucocerebrosidase Activators for the Treatment of Gaucher Disease and Central Nervous System Proteinopathies, Including Parkinson's Disease

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive evaluation option license to Lysosomal Therapeutics, Inc., a company having a place of business in Boston, Massachusetts, to practice the inventions embodied in U.S. Provisional Patent Application No. 61/420,946, filed December 8, 2010 (HHS Ref. No. E–257–2010/0–US–01) and PCT Patent Application No. PCT/US2011/063928, filed December 8, 2011 (HHS Ref. No. E–257–2010/0–PCT–02), both entitled ''Substituted Pyrazolopyrimidines as Glucocerebrosidase Activators.'' The patent rights in these inventions have been assigned to the United States of America. The prospective exclusive evaluation option license territory may be ''worldwide'', and the field of use may be limited to ''Treatment of Gaucher disease and human central nervous system proteinopathies, including without limitation Parkinson's disease.'' Upon the expiration or termination of the exclusive evaluation option license, Lysosomal Therapeutics, Inc. will have the right to execute an exclusive patent commercialization license which will supersede and replace the exclusive evaluation option license with no greater field of use and territory than granted in the evaluation license.

DATES: Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before August 9, 2012 will be considered.

ADDRESSES: Requests for copies of the patent application(s), inquiries, and comments relating to the contemplated exclusive license should be directed to: Tara L. Kirby, Ph.D., Senior Licensing and Patenting Manager, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; Telephone: (301) 435–4426; Facsimile: (301) 402–0220; Email: *tarak@mail.nih.gov.* A signed confidentiality nondisclosure agreement will be required to receive copies of any patent applications that have not been published or issued by the United States Patent and Trademark Office or the World Intellectual Property Organization.

SUPPLEMENTARY INFORMATION: Gaucher disease is a rare lysosomal storage disease caused by mutations in the glucocerebrosidase (GCase) gene; GCase is localized in the lysosome and is responsible for the breakdown of glucocerebroside, an intermediate in glycolipid metabolism. This technology provides small molecule activators of GCase that facilitate the proper folding of GCase and its transport to the lysosome, without inhibiting its activity in the lysosome. Thus, these compounds are extremely promising candidates for the development of a small molecule drug to treat Gaucher disease. Mutations in the GCase gene have also been associated with the development of Parkinson's disease, and therefore, these compounds may also be useful for the treatment of Parkinson's disease. It is also possible that these compounds could be utilized to treat other proteinopathy-based diseases.

The prospective exclusive evaluation option license will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive evaluation option license may be granted unless within fifteen (15) days from the date of this published notice, the NIH receives written

evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Only applications for a license in the field of use set forth in this notice and filed in response to this notice will be treated as objections to the grant of the contemplated exclusive license. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: July 18, 2012.

Richard U. Rodriguez,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 2012–18053 Filed 7–24–12; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HOMELAND SECURITY

Federal Emergency Management Agency

[Docket ID FEMA–2011–0022]

Preliminary Damage Assessment for Individual Assistance Operations Manual (9327.2–PR)

AGENCY: Federal Emergency Management Agency, DHS.

ACTION: Notice of availability.

SUMMARY: This document provides notice of the availability of the final *Preliminary Damage Assessment for Individual Assistance Operations Manual* (9327.2–PR). The Federal Emergency Management Agency (FEMA) published a notice of availability and request for comment for the proposed policy on October 13, 2011.

DATES: This manual is effective July 18, 2012.

ADDRESSES: This final manual is available online at *http://www.regulations.gov* and on FEMA's Web site at *http://www.fema.gov.* The proposed and final manual, all related **Federal Register** Notices, and all public comments received during the comment period are available at *http://www.regulations.gov* under docket ID FEMA–2011–0022. You may also view a hard copy of the final manual at the Office of Chief Counsel, Federal Emergency Management Agency, Room 835, 500 C Street SW., Washington, DC 20472.

FOR FURTHER INFORMATION CONTACT: Michael M. Grimm, Individual Assistance Director, Individual Assistance Division, Federal Emergency Management Agency, 500 C Street SW., Washington, DC 20472, 202–212–1000.

SUPPLEMENTARY INFORMATION: The *Preliminary Damage Assessment for Individual Assistance Operations Manual* (PDA Manual) was developed to create uniform procedures for performing Individual Assistance (IA) Preliminary Damage Assessments (PDAs), nationwide, in response to an impacted State's request. The primary purpose for conducting IA PDAs is to identify the impact, type, and extent of disaster damages and to determine the impact on individuals and communities while identifying the resources needed for the community to recover.

The PDA is an important first step in the disaster declaration process. The information collected during a PDA will be used by the State to determine if the response and recovery actions will require Federal support. If the Governor determines that the State does not have adequate resources to respond and recover from the disaster, and supplemental Federal assistance is required, the Governor may request a Presidential emergency or major disaster declaration under sections 401 and 501 of the Robert T. Stafford Disaster Relief and Emergency Assistance Act, as amended (42 U.S.C. 5170 and 5191). The PDA information, along with the Governor's request, is included with the *Regional Administrator's Validation and Recommendation* and is forwarded to FEMA for review. FEMA then prepares a recommendation to the President based on the PDA information and the *Regional Administrator's Validation and Recommendation.* Establishing a single set of PDA procedures ensures that regardless of the location, type of disaster, or FEMA regional office involved, the assessment of damages will be consistent, thorough, and well coordinated.

The PDA Manual supersedes FEMA Manual 9327.1 PR, *Preliminary Damage Assessment for Individual Assistance Operations Manual,* dated April 2005. It incorporates procedures developed and used by individual FEMA regional offices in the course of conducting PDAs throughout the United States in a variety of disasters over several years. It reflects FEMA's extensive experience working with State and local governments. The PDA Manual is intended to set the standard for defining and recording levels of damage, as well as to establish uniformity in the composition of teams and the means by which data is collected.

FEMA received 10 comments on the draft PDA Manual and made revisions accordingly. This final PDA Manual does not have the force or effect of law.

Authority: The PDA Manual is consistent with and supports the current plans and procedures of the National Response Framework for implementation of the Robert T. Stafford Disaster Relief and Emergency Assistance Act, as amended, 42 U.S.C. 5121 *et seq.* and its implementing regulations in Title 44, Chapter I of the Code of Federal Regulations.

W. Craig Fugate,

Administrator, Federal Emergency Management Agency.

[FR Doc. 2012–18133 Filed 7–24–12; 8:45 am]

BILLING CODE 9111–23–P

DEPARTMENT OF HOMELAND SECURITY

U.S. Citizenship and Immigration Services

[OMB Control No. 1615–0072]

Agency Information Collection Activities: Application for Suspension of Deportation or Special Rule Cancellation of Removal (Pursuant to Section 203 of Public Law 105–100, NACARA), Form I–881; Extension of a Currently Approved Information Collection; Comment Request

ACTION: 30-Day Notice.

The Department of Homeland Security, U.S. Citizenship and Immigration Services (USCIS) will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and clearance in accordance with the Paperwork Reduction Act of 1995. The information collection was previously published in the **Federal Register** on April 18, 2012, at 77 FR 23271, allowing for a 60-day public comment period. USCIS did not receive comments in response to this information collection notice.

The purpose of this notice is to allow an additional 30 days for public comments. Comments are encouraged and will be accepted until August 24, 2012. This process is conducted in accordance with 5 CFR 1320.10.

Written comments and/or suggestions regarding the item(s) contained in this notice, especially regarding the estimated public burden and associated response time, should be directed to the Department of Homeland Security (DHS), and to the Office of Management and Budget (OMB) USCIS Desk Officer. Comments may be submitted to: USCIS, Chief, Regulatory Coordination